Compare ClearPoint Neuro Inc (CLPT) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Target Corporation — how do they compare? ClearPoint Neuro Inc trades at $15.69 (market cap $478.63M), while Target Corporation trades at $137.63 (market cap $60.86B). The key difference: Target Corporation is far larger — about 127.2× ClearPoint Neuro Inc's market cap, and Target Corporation pays a 3.46% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | TGT | |
|---|---|---|
Market Cap | $478.63M | $60.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $141.19 |
52-Week Low | $8.66 | $83.68 |
Enterprise Value | $506.63M | $76.16B |
Dividend Yield | — | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Target (TGT) trades at $134.77, down 0.27% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company maintains stable revenue around $106.6 billion (2025) and has beaten earnings estimates for three consecutive quarters. Recent dividend payments of $1.14 and $1.16 per share highlight its shareholder returns, while analyst consensus leans toward a buy rating with a $137 price target.
TGT presents a balanced opportunity with solid fundamentals and moderate valuation, but faces risks from competitive retail pressures and margin compression. Upside is supported by consistent earnings beats and dividend reliability, though investors should monitor consumer spending trends and inventory management challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
